vs
Side-by-side financial comparison of NewAmsterdam Pharma Co N.V. (NAMS) and Recon Technology, Ltd (RCON). Click either name above to swap in a different company.
NewAmsterdam Pharma Co N.V. is the larger business by last-quarter revenue ($19.1M vs $12.2M, roughly 1.6× Recon Technology, Ltd). Recon Technology, Ltd runs the higher net margin — -6.8% vs -90.7%, a 83.9% gap on every dollar of revenue. On growth, NewAmsterdam Pharma Co N.V. posted the faster year-over-year revenue change (740.1% vs 111.0%).
Kite Pharma, Inc. is an American biotechnology company that develops cancer immunotherapy products with a primary focus on genetically engineered autologous CAR T cell therapy - a cell-based therapy which relies on chimeric antigen receptors and T cells. Founded in 2009, and based in Santa Monica, California, it was acquired by Gilead Sciences in 2017.
Recon Instruments Inc. was a Canadian technology company that produced smartglasses and wearable displays marketed by the company as "heads-up displays" for sports. Recon's products delivered live activity metrics, GPS maps, and notifications directly to the user's eye. Recon's first heads-up display offering was released commercially in October 2010, roughly a year and a half before Google introduced Google Glass.
NAMS vs RCON — Head-to-Head
Income Statement — Q2 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $19.1M | $12.2M |
| Net Profit | $-17.4M | $-832.7K |
| Gross Margin | — | 33.5% |
| Operating Margin | -186.1% | -14.6% |
| Net Margin | -90.7% | -6.8% |
| Revenue YoY | 740.1% | 111.0% |
| Net Profit YoY | 55.5% | 70.5% |
| EPS (diluted) | $-0.15 | $-0.09 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $12.2M | ||
| Q2 25 | $19.1M | — | ||
| Q4 24 | $12.8M | $5.8M | ||
| Q3 24 | $29.1M | — | ||
| Q4 23 | — | $6.4M | ||
| Q2 23 | $8.6M | — |
| Q4 25 | — | $-832.7K | ||
| Q2 25 | $-17.4M | — | ||
| Q4 24 | $-92.2M | $-2.8M | ||
| Q3 24 | $-16.6M | — | ||
| Q4 23 | — | $-3.2M | ||
| Q2 23 | $-42.0M | — |
| Q4 25 | — | 33.5% | ||
| Q2 25 | — | — | ||
| Q4 24 | — | 31.7% | ||
| Q3 24 | — | — | ||
| Q4 23 | — | 26.7% | ||
| Q2 23 | — | — |
| Q4 25 | — | -14.6% | ||
| Q2 25 | -186.1% | — | ||
| Q4 24 | -338.5% | -63.9% | ||
| Q3 24 | -85.9% | — | ||
| Q4 23 | — | -50.4% | ||
| Q2 23 | -461.8% | — |
| Q4 25 | — | -6.8% | ||
| Q2 25 | -90.7% | — | ||
| Q4 24 | -721.7% | -48.9% | ||
| Q3 24 | -57.2% | — | ||
| Q4 23 | — | -49.8% | ||
| Q2 23 | -486.9% | — |
| Q4 25 | — | $-0.09 | ||
| Q2 25 | $-0.15 | — | ||
| Q4 24 | $-0.91 | $-0.31 | ||
| Q3 24 | $-0.18 | — | ||
| Q4 23 | — | $-1.16 | ||
| Q2 23 | $-0.51 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $739.2M | $10.7M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $778.5M | $66.4M |
| Total Assets | $815.1M | $77.6M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $10.7M | ||
| Q2 25 | $739.2M | — | ||
| Q4 24 | $834.2M | $19.9M | ||
| Q3 24 | $422.7M | — | ||
| Q4 23 | — | $36.0M | ||
| Q2 23 | — | — |
| Q4 25 | — | $66.4M | ||
| Q2 25 | $778.5M | — | ||
| Q4 24 | $757.5M | $66.9M | ||
| Q3 24 | $378.9M | — | ||
| Q4 23 | — | $60.0M | ||
| Q2 23 | $398.4M | — |
| Q4 25 | — | $77.6M | ||
| Q2 25 | $815.1M | — | ||
| Q4 24 | $864.6M | $74.2M | ||
| Q3 24 | $439.2M | — | ||
| Q4 23 | — | $68.1M | ||
| Q2 23 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-37.7M | $-1.9M |
| Free Cash FlowOCF − Capex | $-37.8M | — |
| FCF MarginFCF / Revenue | -197.2% | — |
| Capex IntensityCapex / Revenue | 0.5% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-119.7M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-1.9M | ||
| Q2 25 | $-37.7M | — | ||
| Q4 24 | $-37.5M | $-1.7M | ||
| Q3 24 | $-12.5M | — | ||
| Q4 23 | — | $-931.0K | ||
| Q2 23 | $-31.9M | — |
| Q4 25 | — | — | ||
| Q2 25 | $-37.8M | — | ||
| Q4 24 | $-37.5M | — | ||
| Q3 24 | $-12.6M | — | ||
| Q4 23 | — | — | ||
| Q2 23 | $-31.9M | — |
| Q4 25 | — | — | ||
| Q2 25 | -197.2% | — | ||
| Q4 24 | -293.5% | — | ||
| Q3 24 | -43.2% | — | ||
| Q4 23 | — | — | ||
| Q2 23 | -369.3% | — |
| Q4 25 | — | — | ||
| Q2 25 | 0.5% | — | ||
| Q4 24 | 0.0% | — | ||
| Q3 24 | 0.3% | — | ||
| Q4 23 | — | — | ||
| Q2 23 | 0.1% | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
